Patent Foramen Ovale Closure Without Echocardiography Are We Closing the Door Too Fast Too Soon?⁎⁎Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology. by Sorajja, Paul & Nishimura, Rick A.
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ithout Echocardiography
re We Closing the Door Too Fast Too Soon?*
aul Sorajja, MD, FACC,
ick A. Nishimura, MD, FACC
ochester, Minnesota
nterventional cardiologists have firmly established their
ole in the diagnosis and treatment of coronary atheroscle-
osis. Assessment of hemodynamics has also been a long-
tanding role for the catheterization laboratory. However,
he invasive cardiologist is now becoming involved in the
reatment of structural heart disease. Various and increas-
ngly complex procedures are being performed through a
atheter-based approach, such as septal ablation for hyper-
rophic cardiomyopathy, balloon valvotomy, prosthetic leak
epair, and percutaneous valve replacement. The past decade
lso has witnessed the emergence of percutaneous closure of
atent foramen ovale (PFO) for secondary prevention of
troke. This procedure has been rapidly adopted into clinical
ractice with conservative estimates of 11,000 patients
aving received the Amplatzer PFO Occluder (AGA Med-
cal Corporation, Golden Valley, Minnesota) since its in-
roduction worldwide in May 2000 (1).
See page 116
It has been well accepted that catheter therapy for
tructural heart disease requires a team approach of both
nterventionalists and cardiovascular imaging specialists (2).
he antiquated method of fluoroscopy does not compare to
igh resolution images of echocardiography or computed
omography scan imaging, which can show the direct
elationships of catheters and devices to intracardiac struc-
ures. During PFO closure, transesophageal or intracardiac
chocardiography has been thought to be essential to assist
ith defect sizing, to ensure device fit, and to examine for
esidual shunting or other persistent structural defects that
eed to be addressed after deployment of the device. The
oncomitant use of intraprocedural echocardiography does
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.c
From the Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic,
ochester, Minnesota.equire either training in ultrasound imaging or partnership
ith noninvasive colleagues who need to be available during
he procedure.
In the current issue of In this issue of JACC: Cardiovas-
ular Interventions, Wahl et al. (3) provide important new
ata on percutaneous PFO closure performed without the
eed for adjunctive intraprocedural echocardiography. In
his study, the authors extend their previous observations
nd examined 620 patients who underwent percutaneous
FO closure for secondary prevention of presumed para-
oxical embolism (3,4). The salient findings of their report
re successful device deployment in all patients, acute
omplications in 0.8%, complete closure of the defect in
1% of patients, and occurrence of embolic events in 13
atients (2.1%) during median follow-up of 2.6 years (97%
omplete). These results were achieved with empiric use of
he Amplatzer PFO Occluder (AGA Medical Corporation)
hat was deployed with techniques using only fluoroscopy.
hese data have led the authors to propose that adjunctive,
ntraprocedural echocardiography is no longer necessary for
erforming percutaneous PFO closure.
Elimination of the need for adjunctive echocardiography
uring PFO closure has enormous implications for this
elatively new procedure. Certainly, there would be cost
avings with no need for echocardiographic equipment, and
n cases where transesophageal echocardiography is used,
eneral anesthesia is avoided. Procedure time would be
hortened (median of 22 min in Wahl et al. [3]). Interven-
ionalists without training in echocardiography would be at
iberty to perform percutaneous PFO closure without the
id of noninvasive colleagues. In summary, percutaneous
FO closure would become a simpler, shorter procedure,
nd these changes likely would lead to an even wider
tilization of the procedure than has been witnessed thus far.
However, the study of Wahl et al. (3) should not be
isconstrued as suggesting that all interventional cardiolo-
ists can “go it alone” when performing PFO closure.
lthough successful device deployment was achieved in all
atients, these favorable outcomes may well be more related
o the large experience and clinical expertise of their group
600 cases). The catheterization techniques used in this
tudy still require knowledge and a skill set beyond that of
any cardiologists, which must be developed with time and
xperience. For instance, the authors used the “Pacman”
ign on fluoroscopy to indicate proper device deployment
5), which may seem simple but requires a learning curve
nd has not yet been embraced by others performing PFO
losure. Experience with catheter manipulation in the left
trium is essential, particularly as perforations of both atria
nd both appendages during PFO closure have been the
ajor source of complications in other reports (1,6).
Although Wahl et al. (3) state that intraprocedural
chocardiography is no longer needed, a successful PFO
losure procedure does require noninvasive expertise during
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125he initial evaluation and selection of patients. A goal-
riented transesophageal echocardiography performed by a
edicated noninvasive cardiologist is essential for proper
atient selection. Accessory abnormalities such as anoma-
ous pulmonary venous drainage, sinus venous defects, or
ultiple or excessive fenestrations need to be ruled out by
re-procedure imaging. The pre-procedure study also is
eeded to determine device appropriateness and sizing by
xamining the extent of rims, tunnel defects, and relation-
hip of the PFO to other structures such as valves and great
essels. Thus, these procedures need to be done in a center
ith a dedicated team of highly experienced invasive and
oninvasive cardiologists, which may also account for the
igh success of the Swiss group, even if ultrasound is not
sed during the procedure.
The approach of Wahl et al. (3) does decrease procedure
ime and results in cost savings. We must ask ourselves if
heir data truly demonstrate efficacy of this technique, both
n terms of complications as well as outcomes. The authors
Figure 1. Echocardiography During PFO Closure
This patient presented for patent foramen ovale (PFO) closure after cryptogen
tional shunting were evident on pre-procedural transesophageal echocardiogr
After placement of a 14-mm Amplatzer atrial septal defect occluder, severe sh
stretching or tearing of the fossa ovalis membrane. (C) This signiﬁcant shuntin
occluder. (D) Complete closure was ﬁnally obtained with a 22-mm Amplatzer atrial sttribute a low rate of vascular complications to avoiding
ntracardiac echocardiography. However, such complica-
ions persisted in their study, can be minimized with careful
enous access, and on the whole should be avoidable in
xperienced hands even with the use of large ultrasound
atheters. The question as to whether patient outcomes are
imilar with their technique versus the conventional ultra-
ound assisted technique is still unclear. Evaluation of the
fficacy of PFO closure is difficult as the goal is to prevent an
vent that has low frequency and may occur due to other
echanisms. For instance, “favorable rates” of recurrent
mbolism were present after PFO closure; recurrent embo-
ism occurred at a lower frequency (2.1% over mean
ollow-up of 3.0 years) than has been observed in patients
anaged medically (3.8% to 12.0% at 1 year), and compa-
able to previous transcatheter closure studies (0% to 4.9% at
year) (7,8). However, previous studies of recurrent embo-
ism have been limited by small numbers of patients,
ifferent antiplatelet and anticoagulation regimens, and use
ke. (A) A PFO and an atrial septal aneurysm with a single defect and bidirec-
not shown) and intraprocedural intracardiac echocardiography (shown). (B)
at the inferior margin of the device remained (arrow), presumably due to
ow) remained despite placement of an 18-mm Amplatzer atrial septal defectic stro
aphy (
unting
g (arreptal defect occluder. LA  left atrium; RA  right atrium.
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126f varying devices including technologies that are no longer
vailable. Selection bias, markedly different baseline patient
isk, and the multiple potential etiologies for stroke (e.g.,
trial fibrillation, aortic atherosclerosis, and so on) make
omparisons across these studies extremely difficult, thereby
educing the validity of recurrent embolism as a comparative
nd point.
The other end point to measure “success” is the presence
nd degree of residual shunting. In this study, successful
evice deployment occurred in all patients, but residual
hunting occurred in 9% at follow-up, including moderate
r severe shunting in 3%. Moreover, among the 78 patients
ho received a larger 35-mm device, residual shunting
ccurred in 27% and was moderate or severe in 8%. The
egree of residual shunting is notable because these same
nvestigators have reported residual shunt to be the only
redictor of recurrent embolism after PFO closure, and that
ncremental benefit of PFO closure over medical therapy
ccurs in those with complete occlusion (9–12). In other
tudies where intraprocedural echocardiography was uti-
ized, complete shunt elimination occurred in 98% to 99%
f patients (13,14). It is important to consider that the goal
f PFO closure may not be simply to decrease the size of a
hunt, but to eliminate all shunting and thereby completely
bolish the risk of paradoxical embolism. It is not clear
hether or not knowledge of the residual shunt during the
rocedure would have led to changes in deployment, par-
icularly as it is known that many patients have improve-
ent of the shunt during follow-up (14,15). Nonetheless,
e and others have utilized either different or multiple
evices when confronted with new intraprocedural echocar-
iographic findings (Fig. 1) (16). In the current study, there
ere 8 patients who required a second closure for persistent
esidual shunt in follow-up, which might have been avoided
y intraoperative echocardiography. Perhaps selective use of
ntraoperative imaging may be useful, for patients with
unnel defects, atrial septal aneurysms, and those requiring a
arger device who had an increased incidence of post-
rocedure shunting.
Finally, the major question that must be addressed is not
ow the procedure can be done faster and better but
hether a PFO closure should be done at all to prevent
ecurrent stroke. There still are no definitive data that PFO
losure prevents stroke or its recurrence. At a time when
arefully controlled, randomized studies are needed to
etermine clinical efficacy, important opportunities may
ave been missed when cohorts of600 patients are able to
e done at a single center. Although this important study by
ahl et al. (3) shows that the “door” between the atria can ie closed safely and expeditiously, let us not close the door
o further investigating the true efficacy of this technique.
eprint requests and correspondence: Dr. Paul Sorajja, Mayo
linic, 200 1st Street SW, Rochester, Minnesota 55902. E-mail:
aul.sorajja@mayo.edu.
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